You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
S. PNEUMONIAE AB (IGG) (14 SEROTYPES), MAID |
||
Geisinger Epic Procedure Code: LAB2871
Geisinger Epic ID: 28415
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Alternate Collection Container: |
3.5 mL gold-top (serum separator) tube
|
|
Specimen required: |
0.5 mL aliquot of serum; minimum 0.25 mL. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow to clot. Centrifuge 10 minutes at 3000 rpm. | |
Transport temperature: |
Refrigerated (preferred). Room temperature or frozen specimen also acceptable. | |
Specimen stability: |
Room Temperature: 1 week. Refrigerated: 14 days. Frozen: 90 days. | |
Rejection criteria: |
Stability limits exceeded. | |
TEST DETAILS |
||
Reference interval: |
Evaluation of the response to pneumococcal vaccination is best accomplished by comparing pre-vaccination and post-vaccination antibody levels. A 2- to 4-fold increase in type-specific antibodies measured 4-6 weeks after vaccination is expected in immunocompetent adults. The number of serotypes for which a 2- to 4-fold increase is observed varies greatly among individuals; a consensus panel has suggested that individuals older than 5 years should respond to at least approximately 70% of pneumococcal serotypes. Adults > 65 years old may exhibit a smaller (< 2-fold) increase in type-specific antibody levels. | |
Additional information: |
Serotype designations are American nomenclature, with Danish nomenclature in parentheses. Studies from the 1980s using radioimmunoassay suggested that vaccine-induced S. pneumoniae type-specific antibody levels of approximately 2.0 mcg/mL were protective against invasive pneumococcal disease. Newer methods (ELISA and multiplexed immunoassay) incorporating an adsorption step to remove cross-reactive antibodies yield results that are comparable to each other, but are lower than those obtained with the original radioimmunoassay. Rigorous studies of protective antibody levels as determined by the newer methods have not been performed. In addition to antibody quantity, protection also depends on antibody avidity and opsonophagocytic activity. | |
CPT code(s): |
86317 X 14 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Serotypes 1, 3, 4, 5, 8, 9 (9N), 12 (12F), 14, 19 (19F), 23 (23F), 26 (6B), 51 (7F), 56 (18C), 68 (9V). | |
Methodology: |
Multi-analyte Immunodetection |
|
Synonyms: |
Streptococcus pneumoniae IgG Ab (14 Serotypes). PN14, Quest test code 19564
|
|
Clinical significance: |
The MAID procedure measures IgG antibodies recognizing 14 type-specific pneumococcal polysaccharide antigens included in the polyvalent vaccine (1, 3, 4, 5, 8, 9, 12, 14, 19, 23, 26, 51, 56, and 68). A 2- to 4-fold increase in type-specific antibodies measured 4-6 weeks after vaccination is expected in immunocompetent adults. The number of serotypes for which a 2- to 4-fold increase is observed varies greatly among individuals; a consensus panel has suggested that individuals older than 5 years should respond to at least approximately 70% of pneumococcal serotypes. Adults > 65 years old may exhibit a smaller (< 2-fold) increase in type-specific antibody levels. | |